Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2023-07-19 Regulatory Filings
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
Regulatory Filings Classification · 95% confidence The document is explicitly titled "*PRESS RELEASE*" and announces a specific corporate/clinical development event: the injection of the first patient in a new Phase 1/2 study evaluating NBTXR3. It contains forward-looking statements, contact information typical of a press release, and mentions the company's stock tickers (Euronext: NANO –– NASDAQ: NBTX). This format strongly indicates an immediate public disclosure of material, non-financial news. Since there is no specific category for a general press release announcing clinical trial progress, and it is not a formal regulatory filing like a 10-K, Earnings Release (ER), or a specific financial notice (DIV, CAP), the most appropriate general category for immediate, non-financial corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which often serves as a catch-all for significant announcements not covered by other specific codes. However, given the content is purely operational/clinical news, and not a mandatory regulatory filing disclosure (like a change in management or a dividend), it is best classified as a general announcement. RNS is the best fit among the provided options for a general, non-financial, time-sensitive announcement.
2023-07-19 English
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
Earnings Release Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a major business event: a global licensing, co-development, and commercialization agreement for a drug candidate (NBTXR3) between NANOBIOTIX and Janssen. It details financial terms (upfront fee, milestone payments, royalties) and includes a section for a conference call to discuss the agreement. This type of announcement, focusing on strategic corporate actions, partnerships, and financial implications, is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is a press release announcing significant corporate news rather than a formal regulatory filing like a 10-K or a detailed quarterly report (IR), and it is not a transcript (CT) or a presentation (IP), the most fitting category is Earnings Release (ER), as these often accompany or precede the release of detailed financial results or major strategic updates. Given the context of a major licensing deal, it functions as a significant corporate update, which often falls under the ER umbrella or RNS if no other category fits. However, since it details financial expectations and strategic direction, ER is a strong candidate. If it were purely a notice of a report publication, RPA would apply, but this is the substance of the news itself. I will classify it as ER because it announces key financial and strategic developments, even though it's not strictly quarterly earnings. FY 2023
2023-07-10 English
NANOBIOTIX annonce la signature d’un accord de licence globale pour le co-développement et la commercialisation de NBTXR3, son potentiel radioenhancer first-in-class
Earnings Release Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a major business event: a global licensing, co-development, and commercialization agreement for a drug candidate (NBTXR3) between NANOBIOTIX and Janssen. It details financial terms (upfront fee, milestone payments, royalties) and includes a section for a conference call to discuss the agreement. This type of announcement, focusing on strategic corporate actions, partnerships, and financial implications, is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is a press release announcing significant corporate news rather than a formal regulatory filing like a 10-K or a detailed quarterly report (IR), and it is not a transcript (CT) or a presentation (IP), the most fitting category is Earnings Release (ER), as these often accompany or precede the release of detailed financial results or major strategic updates. Given the context of a major licensing deal, it functions as a significant corporate update, which often falls under the ER umbrella or RNS if no other category fits. However, since it details financial expectations and strategic direction, ER is a strong candidate. If it were purely a notice of a report publication, RPA would apply, but this is the substance of the news itself. I will classify it as ER because it announces key financial and strategic developments, even though it's not strictly quarterly earnings. FY 2023
2023-07-10 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French commercial code (Code de commerce) and AMF regulations (Autorité des Marchés Financiers). The core content is a table showing the total number of shares and voting rights as of May 31, 2023, and states that a new publication will occur if the numbers change. This type of regular disclosure regarding the total share capital and voting rights is a specific regulatory requirement, often related to major shareholdings or capital structure transparency. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit for notifications concerning changes in the total number of shares/voting rights, although it is often used for crossing ownership thresholds. However, given the explicit focus on the total count of shares and voting rights, this is a standard regulatory disclosure related to capital structure transparency. Since there isn't a specific code for 'Monthly Share Capital Disclosure', and it deals with share structure/ownership reporting, MRQ is the most appropriate classification, as these reports often precede or accompany major shareholding changes or are required monthly/quarterly for transparency. It is not an earnings release (ER), a proxy statement (PSI), or a general regulatory filing (RNS) because it is highly specific to share count disclosure.
2023-06-08 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and explicitly references French Commercial Code articles (L.233-8 II) and the French Financial Markets Authority (AMF) regulations regarding the disclosure of the total number of voting rights and shares outstanding as of a specific date (May 31, 2023). This type of periodic disclosure regarding the capital structure and voting rights is a specific regulatory requirement. While it relates to share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS). It is a mandatory regulatory disclosure about the current voting structure. Among the provided codes, 'DVA' (Declaration of Voting Results & Voting Rights Announcements) is the closest fit for official announcements detailing voting rights figures, although 'RNS' (Regulatory Filings) is a strong fallback. Given the specific focus on the total number of voting rights as mandated by financial regulations, DVA is the most precise classification for this type of periodic capital structure update.
2023-06-08 English
NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR LE PREMIER TRIMESTRE 2023
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and explicitly states it is providing an "update on its operational progress and its cash position for the first quarter of 2023" ("NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR LE PREMIER TRIMESTRE 2023"). It details key financial highlights (cash position) and pipeline updates for Q1 2023. This structure—a brief announcement summarizing key financial metrics for a specific period (Q1)—is characteristic of an Earnings Release (ER). Although it mentions the upcoming AGM, the primary focus and content relate to the quarterly financial performance update, not the full annual report (10-K) or a comprehensive interim report (IR). It is not merely an announcement of a report (RPA) because it contains the actual summarized results and operational details. Q1 2023
2023-05-17 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.